In July 2025, Endocrine Society delivered the most consequential catalyst for Pentixapharm's late- stage diagnostic asset PentixaFor. Recognising the structural under-diagnosis of primary aldosteronism (PA), updated guidelines now recommend universal screening of all patients with hypertension, rather than restricting testing to traditionally defined high-risk groups. PA is dangerous if missed, but very treatable when detected early. Following detection, patients are subtyped as curable by a single surgery or as victims of lifelong medication. This important subtyping “tool” exists; it’s called adrenal vein sampling (AVS).
LÄS MER
